NASACORT HFA
LOE ApproachingNDANASALSPRAY, METERED
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NASACORT HFA is a metered-dose nasal spray containing triamcinolone acetonide, a corticosteroid approved in 2004 for intranasal use. It is indicated for allergic rhinitis and nasal symptoms associated with allergic conditions. The drug works by reducing inflammation in the nasal passages through local corticosteroid activity.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating teams are likely focused on lifecycle extension and cost management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NASACORT HFA offers limited new-product career momentum but strong foundation in mature brand management and competitive defense strategies. This role is ideal for professionals seeking to develop skills in cost-containment, generic competition strategy, and portfolio optimization in a stable, non-growth environment.
Brand ManagerField Sales Representative
Worked on NASACORT HFA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.